DS
NTLA icon

David Shaw’s Intellia Therapeutics NTLA Stock Holding History

David Shaw’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109M Buy
6,443,323
+715,146
+12% +$10M 0.05% 418
2026
Q1 		$73.4M Buy
5,728,177
+397,113
+7% +$5.06M 0.04% 500
2025
Q4 		$47.9M Buy
5,331,064
+3,102,664
+139% +$42.7M 0.03% 727
2025
Q3 		$38.5M Buy
2,228,400
+1,403,673
+170% +$17.3M 0.02% 791
2025
Q2 		$7.74M Buy
824,727
+792,331
+2,446% +$6.51M 0.01% 1696
2025
Q1 		$230K Sell
32,396
-1,187
-4% -$12K ﹤0.01% 3877
2024
Q4 		$392K Buy
33,583
+21,303
+173% +$332K ﹤0.01% 3759
2024
Q3 		$252K Buy
+12,280
New +$283K ﹤0.01% 4062
2023
Q1 		– Sell
-15,152
Closed -$529K – 4727
2022
Q4 		$529K Sell
15,152
-36,419
-71% -$1.73M ﹤0.01% 3825
2022
Q3 		$2.89M Sell
51,571
-374,779
-88% -$23.2M ﹤0.01% 2676
2022
Q2 		$22.1M Buy
426,350
+207,941
+95% +$10.6M 0.03% 802
2022
Q1 		$15.9M Buy
218,409
+215,775
+8,192% +$18.3M 0.01% 1198
2021
Q4 		$311K Sell
2,634
-7,398
-74% -$927K ﹤0.01% 4662
2021
Q3 		$1.35M Sell
10,032
-104,960
-91% -$15.9M ﹤0.01% 3371
2021
Q2 		$18.6M Sell
114,992
-288,728
-72% -$22.5M 0.02% 1064
2021
Q1 		$32.4M Buy
403,720
+42,349
+12% +$2.84M 0.03% 681
2020
Q4 		$19.7M Buy
361,371
+189,402
+110% +$6.88M 0.02% 964
2020
Q3 		$3.42M Sell
171,969
-22,492
-12% -$469K ﹤0.01% 1973
2020
Q2 		$4.09M Buy
+194,461
New +$3.3M ﹤0.01% 1805
2020
Q1 		– Sell
-12,625
Closed -$185K – 4146
2019
Q4 		$185K Buy
+12,625
New +$176K ﹤0.01% 3819

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's NTLA Position: Q2 2026 in Review

David Shaw increased its Intellia Therapeutics (NTLA) stake by 12% in Q2 2026, buying an estimated $10M and bringing the position to 6,443,323 shares worth $109M. The position accounts for 0.05% of the portfolio, ranked #418.

David Shaw first reported a position in NTLA in Q4 2019 and has held it in 20 quarters since. 326 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • David Shaw held 6,443,323 shares of Intellia Therapeutics worth $109M as of Q2 2026.
  • David Shaw bought 715,146 Intellia Therapeutics shares in Q2 2026, an estimated $10M.
  • Intellia Therapeutics made up 0.05% of David Shaw's portfolio in Q2 2026, its #418 holding.
  • David Shaw first reported a position in Intellia Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • 326 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.